Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes

Diagnostic and prognostic roles of IRAK1 in hepatocellular carcinoma tissues: an analysis of immunohistochemistry and RNA-sequencing data from the cancer genome atlas

(2017) Zhi-hua Ye et al.   OncoTargets and Therapy

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia

(2017) Alyssa Carey et al.   Cell Reports

Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial

(2017) Ruben A Mesa et al.   Lancet Haematology

Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor-treated CML stem cells

(2016) B. Zhang et al.   BLOOD

FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia

(2016) Elie Traer et al.   CANCER RESEARCH

Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis

(2015) R. S. Komrokji et al.   BLOOD

Treatment of Chronic Myelogenous Leukemia by Blocking Cytokine Alterations Found in Normal Stem and Progenitor Cells

(2015) Robert S. Welner et al.   CANCER CELL

Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies

(2015) Zhaoyang Li et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting IRAK1 in T-cell acute lymphoblastic leukemia

(2015) Charles Dussiau et al.   Oncotarget

IRAK1: oncotarget in MDS and AML

(2015) Levi J. Beverly et al.   Oncotarget

BCR-ABL1 promotes leukemia by converting p27 into a cytoplasmic oncoprotein

(2014) A. Agarwal et al.   BLOOD

IRAK signalling in cancer

(2014) G W Rhyasen et al.   BRITISH JOURNAL OF CANCER

PhosphoSitePlus, 2014: mutations, PTMs and recalibrations

(2014) Peter V. Hornbeck et al.   NUCLEIC ACIDS RESEARCH

Interleukin 1 receptor-associated kinase 1 (IRAK1) mutation is a common, essential driver for Kaposi sarcoma herpesvirus lymphoma

(2014) D. Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

IL-1 Receptor-Associated Kinase Signaling and Its Role in Inflammation, Cancer Progression, and Therapy Resistance

(2014) Ajay Jain et al.   Frontiers in Immunology

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia

(2013) G. Yang et al.   BLOOD

Outcome of older patients with acute myeloid leukemia

(2013) Mya S. Thein et al.   CANCER

Targeting IRAK1 as a Therapeutic Approach for Myelodysplastic Syndrome

(2013) Garrett W. Rhyasen et al.   CANCER CELL

Differential IRAK signaling in hematologic malignancies

(2013) Garrett W. Rhyasen et al.   EXPERIMENTAL HEMATOLOGY

Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3–Internal Tandem Duplication Status

(2013) Jorge E. Cortes et al.   JOURNAL OF CLINICAL ONCOLOGY

MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia

(2013) C Jiménez et al.   LEUKEMIA

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS

(2012) L. Barreyro et al.   BLOOD

Structure-based design of oxygen-linked macrocyclic kinase inhibitors: discovery of SB1518 and SB1578, potent inhibitors of Janus kinase 2 (JAK2) and Fms-like tyrosine kinase-3 (FLT3)

(2012) Anders Poulsen et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

FLT3-Mediated p38-MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis

(2011) C. Desterke et al.   CANCER RESEARCH

Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes

(2011) Sigurdur Y. Kristinsson et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma

(2011) Anthony D. William et al.   JOURNAL OF MEDICINAL CHEMISTRY

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

(2011) S Hart et al.   LEUKEMIA

Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

(2011) Theonie Anastassiadis et al.   NATURE BIOTECHNOLOGY

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia

(2011) S Hart et al.   Blood Cancer Journal

MicroRNA-146a disrupts hematopoietic differentiation and survival

(2010) Daniel T. Starczynowski et al.   EXPERIMENTAL HEMATOLOGY

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

Helical assembly in the MyD88–IRAK4–IRAK2 complex in TLR/IL-1R signalling

(2010) Su-Chang Lin et al.   NATURE

TLR8-dependent TNF-  overexpression in Fanconi anemia group C cells

(2009) S. M. Vanderwerf et al.   BLOOD